Examination of Inter‐α Inhibitor Proteins in Permanent and Transient Focal Ischemia
Our data highlight the contribution of interlaboratory heterogeneity to study outcomes and suggest that interventions considered for clinical development should undergo rigorous testing in multiple single-laboratory studies before entering a multicenter preclinical trial.
Authors
- Cenk Ayata (ORCID: https://orcid.org/0000-0002-3644-6042)
- Yow‐Pin Lim (ORCID: https://orcid.org/0000-0003-2697-7963)
- Takahiko Imai (ORCID: https://orcid.org/0000-0002-4422-2946)
- Andreia Morais (ORCID: https://orcid.org/0000-0002-9351-2552)
- Tao Qin (ORCID: https://orcid.org/0009-0005-2364-1868)
- Yuichi Sasaki (ORCID: https://orcid.org/0009-0003-1833-4041)
Institutions
- Harvard University (US)
- Providence College (US)
- Brown University (US)
- Massachusetts General Hospital (US)
- ProThera Biologics (United States) (US)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-02-08
- DOI
- https://doi.org/10.1161/jaha.124.036034
- Primary Topic
- Acute Ischemic Stroke Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00